The seroepidemiology of rubella in western Europe.
Most of the countries in western Europe have now implemented mass infant rubella immunization programmes, instead of or in addition to selective vaccination in order to achieve the elimination of congenital rubella syndrome. The European countries Denmark, England and Wales, Finland, France, Germany, Italy and the Netherlands undertook large, national serological surveys collecting several thousand serum specimens during 1994-8. Antibodies against rubella virus were detected by a variety of enzyme immuno-assays. Comparability of the assay results was achieved by a standardized methodology. The age- and sex-stratified serological results were related to the schedules, coverage of rubella vaccination and the incidence in these countries. The results show widely differing levels of immunity to rubella both in the general population and in the specific age groups of males and females. A low rate (< 5%) of susceptibles in childhood and adolescents of both sexes was obtained only in Finland and the Netherlands. Countries such as Italy with only moderate coverage for the infant immunization programme currently have both high susceptibility levels in the general population and in the at-risk population. The likelihood is of continued epidemics of rubella with cases of congenital rubella syndrome. The continued implementation of selective vaccination will help to offset the impact of this ongoing transmission and to protect women on reaching childbearing age.
Pebody
R G
RG
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London, UK.
Edmunds
W J
WJ
Conyn-van Spaendonck
M
M
Olin
P
P
Berbers
G
G
Rebiere
I
I
Lecoeur
H
H
Crovari
P
P
Davidkin
I
I
Gabutti
G
G
Gerike
E
E
Giordano
C
C
Hesketh
L
L
Plesner
A M
AM
Raux
M
M
Rota
M C
MC
Salmaso
S
S
Tischer
A
A
Valle
M
M
Miller
E
E
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000917:Antibody Formation; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D017589:Immunization Programs; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D012409:Rubella / Q000453:epidemiology* / Q000276:immunology; D012411:Rubella Vaccine; D016036:Seroepidemiologic Studies
D012411:Rubella Vaccine